See how CGP may help you understand which treatment options may work best.
We’re here for you every step of the testing process
Whether you’re just learning about the FoundationOne®CDx test or are further along in the testing process, we’re dedicated to providing the resources, support, and assistance you and your loved ones need.
Coverage information and financial resources
Giving you access to insurance, billing, and financial assistance is a top priority at Foundation Medicine—and FoundationAccessTM is here to help.
All Foundation Medicine tests are covered by Original Medicare and Medicare Advantage for qualifying patients. Qualifying patients with Original Medicare have no out-of-pocket costs for Foundation Medicine comprehensive genomic profiling (CGP) tests.1
Patient out-of-pocket costs will vary depending on your insurance. For those with out-of-pocket costs, financial assistance may be available.* Anyone can apply at any time to see if they qualify. Complete an online form or this PDF application.
Or talk to a Client Services team member at:
*Financial assistance is only available for tests ordered within the U.S. and its territories.
We will be in touch
After your doctor orders a test and our lab receives your sample, we’ll reach out to you by phone, or mail, with important information about what you can expect as your test moves forward.
Important resources for help and support
Knowledge is power. We’ve created the following resources to help you and your loved ones feel educated and confident as you make decisions around your cancer care.
The Foundation Medicine Approach to Personalized Cancer Treatment
Watch this video for a simple explanation of the basics of cancer and common treatment options.
Ed and Sandy’s Story
See how the FoundationOne CDx test helped a patient with Stage 4 colon cancer and his loved one create a personalized cancer treatment plan together.
*Metastatic colorectal cancer (mCRC) is a complex disease, and mCRC patients have a 14% survival rate five years after their diagnosis.3 43% of mCRC patients are matched to an on-label therapy, but a match does not guarantee that the treatment is right for a patient or that a patient will achieve a similar outcome.4 Speak with your doctor for more information.
Stay connected. Stay informed.
Advanced cancer can come with many unknowns. Foundation Medicine is committed to keeping you and your loved ones informed, educated, and empowered. Sign up to receive email updates from us.
- Medicare and Medicare Advantage members have coverage of FoundationOne CDx
- A select number of commercial payers have developed medical policy coverage for Foundation Medicine’s FoundationOne CDx
- American Cancer Society. Cancer Facts & Figures 2021. Atlanta, GA: American Cancer Society; 2021.
- Data on file. Foundation Medicine, 2020.
Other important information about FoundationOne CDx
Intended Use Statement
FoundationOne®CDx is a qualitative next-generation sequencing based in vitro diagnostic test for advanced cancer patients with solid tumors and is for prescription use only. The test analyzes 324 genes as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) and is a companion diagnostic to identify patients who may benefit from treatment with specific therapies in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Some patients may require a biopsy. For the complete label, including companion diagnostic indications and important risk information, please visit www.F1CDxLabel.com.
Other important information about FoundationOne®Liquid CDx
FoundationOne®Liquid CDx is for prescription use only and is a qualitative next-generation sequencing based in vitro diagnostic test for advanced cancer patients with solid tumors. The test analyzes 324 genes utilizing circulating cell-free DNA and is FDA-approved to report short variants in 311 genes and as a companion diagnostic to identify patients who may benefit from treatment with specific therapies (listed in Table 1 of the Intended Use) in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Patients being considered for eligibility for therapy based on detection of NTRK1/2/3 and ROS1 fusions should only be tested if tissue is unavailable. Patients who are negative for companion diagnostic mutations should be reflexed to tumor tissue testing and mutation status confirmed using an FDA-approved tumor tissue test, if feasible. For the complete label, including companion diagnostic indications and complete risk information, please visit www.F1LCDxLabel.com.